Outcome trials of COX-2 selective inhibitors: Global safety evaluation does not promise benefits

European Journal of Clinical Pharmacology

Volumn 59, Issue 2, 2003, Pages 169-175

  Gomez Cerezo, Jorge ^a   Lubomirov Hristov, Rubin ^a   Carcas Sansuán, Antonio J ^a   Vázquez Rodríguez, Juan J ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

COX 2 selective inhibitors; Gastrointestinal safety; Gastroprotective cotherapy; Global safety; Nonsteroidal anti inflammatory drugs; Outcome trials

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; ROFECOXIB;

ABDOMINAL PAIN; ARTICLE; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG COST; DRUG RESEARCH; DRUG SAFETY; EDEMA; ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HEART INFARCTION; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; INTESTINE ULCER; KIDNEY DISEASE; LABORATORY TEST; LIVER DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; STOMACH ULCER; THROMBOSIS; TREATMENT OUTCOME;

EID: 0037715245     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0579-1     Document Type: Article

References (35)

1. Singh G (1998) Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 105(1B):31-38
2. McCarthy D (1998) Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology. Am J Med 105(5A):3-9
3. Laine L (2001) Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 120:594-606
4. Silverstein FE, Graham DY, Senior JR et al. (1995) Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123:241-249
5. Silverstein FE, Faich G, Goldstein JL et al. (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247-1255
6. Bombardier C, Laine L, Reicin A et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343:1520-1528
7. Goldstein JL, Silverstein FE, Agrawal NM et al. (2000) Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 95:1681-1690
8. Langman MJ, Jensen DM, Watson DJ et al. (1999) Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 282:1929-1933
9. Goldstein JL, Correa P, Zhao WW et al. (2001) Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared with naproxen in patients with arthritis. Am J Gastroenterol 96:1019-1027
10. Hawkey C, Laine L, Simon T et al. (2000) Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 43:370-377
11. FDA Advisory Committee (2000). Celecoxib Medical Officer's Gastroenterology Review (CLASS Study). http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_05_gi.pdf
12. FDA Advisory Committee (2000). Celecoxib Statistical Review (CLASS study). http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_04_stats.pdf
13. FDA Advisory Committee (2000). Rofecoxib Statistical Review (VIGOR study). http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_04_stats.pdf
14. FDA Advisory Committee (2000). Celecoxib Medical Officer Review (CLASS study). http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_03_med.pdf
15. Goldstein JL, Eisen GM, Stenson W et al. (2001) Significant reduction in serious upper gastrointestinal (UGI) events with celecoxib, a COX-2 specific inhibitor, compared with conventional NSAIDs. The SUCCESS I Trial (abstract). Gastroenterology 120:105
16. Jüni P, Rutjes AW, Dieppe PA (2002) Pharmacia addresses June 1 editorial regarding CLASS study: authors' response. BMJ 325:163-164
17. Geis GS (2002) Are selective COX-2 inhibitors superior to traditional NSAIDs? Pharmacia's response to editorial. BMJ 325:161-162
18. Jüni P, Rutjes AWS, Dieppe PA (2002) Are selective COX-2 inhibitors superior to traditional nonsteroidal anti-inflammatory drugs? (editorial) BMJ 324:1287-1288
19. Deeks JJ, Smith LA, Bradley MD (2002) Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomized controlled trials. BMJ 325:619-623
20. Wright JM (2002) A missed opportunity (electronic response to: Deeks et al. 2002 Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomized controlled trials. BMJ 325:619-623) BMJ http://bmj.com/cgi/eletters/325/7365/619#26374 (accessed 22 November 2002)
21. Jüni P, Sterchi R, Dieppe PA (2002) Problems compromising the review's validity. (electronic response to: Deeks et al. 2002 Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomized controlled trials. BMJ 325:619-623) BMJ http://bmj.com/cgi/eletters/325/7365/619#26374 (accessed 22 November 2002)
22. Jones R (2002) Efficacy and safety of COX-2 inhibitors. New data are encouraging but the risk-benefit ratio remains unclear (editorial). BMJ 325:607-608
23. Wright JM (2002) The double-edged sword of COX-2 selective NSAIDs. CMAJ 167:1131-1137
24. Bobbio M, Demichelis B, Giustetto G (1994) Completeness of reporting trials results: effect on physicians' willingness to prescribe. Lancet 343:1209-1211
25. Shield MJ, Morant SV (1996) Misoprostol in patients taking nonsteroidal anti-inflammatory drugs (letter). BMJ 312:846
26. Mamdani M, Rochon P, Laupacis A, Anderson G (2002) Initial patterns of use of COX-2 inhibitors by elderly patients in Ontario: findings and implications. CMAJ 167:1125-1126
27. Mamdani M, Rochon PA, Juurlink DN et al. (2002) Observational study of upper gastrointestinal hemorrhage in elderly patients given selective cyclooxygenase-2 inhibitors or conventional nonsteroidal anti-inflammatory drugs. BMJ 325:624-629
28. Villa LF (ed) (2001) Medimecum: guía de terapia farmacológica, 6th edn. Adis, Madrid
29. Chan FKL, Chung SCS, Suen BY et al. (2001) Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344:967-973
30. Marshall JK, Pellissier JM, Attard CL, Kong SX, Marentette MA (2001) Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs on osteoarthritis. Pharmacoeconomics 19:1039-1049
31. Moore, RA, Phillips CJ, Pellissier JM, Kong SX (2001) Health economics comparisons of rofecoxib versus conventional nonsteroidal anti-inflammatory drugs for osteoarthritis in the United Kingdom. J Med Econ 4:1-7
32. Burke TA, Zabinski RA, Pettitt D, Maniadakis N, Maurath CJ, Goldstein JL (2001) A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis. Pharmacoeconomics (Suppl 1) 19:33-47
33. Peterson WL, Cryer B (1999) COX-1-Sparing NSAIDs Is the enthusiasm justified? (editorial) JAMA 282:1961-1963
34. Mayordomo J (2002) Sanidad extiende a toda España un modelo andaluz de control de recetas: La medida se aplicará a los antiinflamatorios Vioxx y Celebrex. El Pals 19 June, p 42
35. Dirección General de Farmacia y Productos Sanitarios (DGFPS) (2002) Resolución que establece la necesidad de visado de inspección previo a su dispensación con cargo al Sistema Nacional de Salud para las especialidades de Celebrex y Vioxx. Ministrerio de Sanidad y Consumo. 17 June 2002